Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Hansson

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Leukemia|January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human studyNoffar Bar, Thomas Martin, Craig C Hofmeister, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Cancers|March 13, 2024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study GroupAnu Partanen, Anders Waage, Valdas Peceliunas, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Blood Cancer Journal|April 20, 2021
Germline variants at SOHLH2 influence multiple myeloma riskLaura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, et al.
The New England Journal of Medicine|April 28, 2016
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPhilippe Moreau, Tamás Masszi, Norbert Grzasko, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Blood Cancer Journal|October 17, 2020
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)María-Victoria Mateos, Shaji Kumar, Meletios A Dimopoulos, et al.
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
BMC Cancer|February 6, 2022
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trialAlexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Leukemia|January 7, 2026
Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human studyNoffar Bar, Thomas Martin, Craig C Hofmeister, et al.
European Journal of Haematology|May 16, 2017
Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysisPhilippe Moreau, Meletios A Dimopoulos, Paul G Richardson, et al.
Cancers|March 13, 2024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study GroupAnu Partanen, Anders Waage, Valdas Peceliunas, et al.
Hemasphere|November 15, 2019
Insights on Multiple Myeloma Treatment StrategiesMaría-Victoria Mateos, Heinz Ludwig, Ali Bazarbachi, et al.
Blood Cancer Journal|April 20, 2021
Germline variants at SOHLH2 influence multiple myeloma riskLaura Duran-Lozano, Gudmar Thorleifsson, Aitzkoa Lopez de Lapuente Portilla, et al.
The New England Journal of Medicine|April 28, 2016
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple MyelomaPhilippe Moreau, Tamás Masszi, Norbert Grzasko, et al.
Haematologica|March 5, 2026
REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trialsKatarina Uttervall, Martin K Kortum, Aurore Perrot, et al.
Blood Cancer Journal|October 17, 2020
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)María-Victoria Mateos, Shaji Kumar, Meletios A Dimopoulos, et al.
Blood|May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaMeletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
BMC Cancer|February 6, 2022
Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trialAlexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, et al.
Pageof 9